BRIEF-EMA Recommends Restricting Use Of Cancer Medicine Rubraca
European Medicines Agency:
* EMA: EMA RECOMMENDS RESTRICTING USE OF CANCER MEDICINE RUBRACA: 22/07/2022
* EMA - RECOMMENDATION DOES NOT AFFECT USE OF RUBRACA AS MAINTENANCE TREATMENT FOLLOWING CHEMOTHERAPY Source text for Eikon: Further company coverage:
Google News